Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) EBT Margin (2016 - 2025)

Arcadia Biosciences' EBT Margin history spans 12 years, with the latest figure at 152.61% for Q4 2025.

  • For Q4 2025, EBT Margin rose 17872.0% year-over-year to 152.61%; the TTM value through Dec 2025 reached 51.42%, up 4666.0%, while the annual FY2025 figure was 47.98%, 3743.0% up from the prior year.
  • EBT Margin reached 152.61% in Q4 2025 per RKDA's latest filing, down from 88.48% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 243.33% in Q2 2023 to a low of 331.33% in Q4 2024.
  • Average EBT Margin over 5 years is 85.8%, with a median of 93.45% recorded in 2022.
  • The largest YoY upside for EBT Margin was 352604bps in 2021 against a maximum downside of -99278bps in 2021.
  • A 5-year view of EBT Margin shows it stood at 222.16% in 2021, then soared by 125bps to 54.49% in 2022, then crashed by -205bps to 57.27% in 2023, then crashed by -479bps to 331.33% in 2024, then soared by 54bps to 152.61% in 2025.
  • Per Business Quant, the three most recent readings for RKDA's EBT Margin are 152.61% (Q4 2025), 88.48% (Q3 2025), and 34.43% (Q2 2025).